Compare Alcon AG (ALC) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs McCormick & Company, Incorporated — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while McCormick & Company, Incorporated trades at $53.33 (market cap $14.27B). The key difference: Alcon AG is far larger — about 2.5× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| ALC | MKC | |
|---|---|---|
Market Cap | $35.19B | $14.27B |
Sector | Health | Consumer Staples |
52-Week High | $90.12 | $72.26 |
52-Week Low | $62.02 | $45.60 |
Enterprise Value | $39.03B | $18.87B |
Dividend Yield | 0.49% | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
MKC trades at $52.96, up 1.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67 suggesting 13% upside. The company reported Q2 2026 results that beat expectations, driven by the McCormick de Mexico acquisition and margin expansion, with revenue growth of 16.7% year-over-year. The pending $65 billion merger with Unilever's food business represents a transformative opportunity, though integration risks remain.
The outlook is positive, supported by strong profitability metrics, including a 21.91% net income margin and 25.7% ROE, alongside a reasonable valuation with a P/E of 8.81. Key risks include execution of the Unilever deal, competitive pressures in the consumer segment, and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
